AOBiome

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, AOBiome sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

AOBiome: 11 sponsored US clinical trials, none currently recruiting.

AOBiome sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 2 trials.

Top-decile sponsor footprint

AOBiome ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 2

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
COMPLETED Phase 1

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

NCT03775434
COMPLETED Phase 2

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

NCT03590366
COMPLETED Phase 2

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

NCT03488563
COMPLETED Phase 2

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
COMPLETED Phase 1

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

NCT03290248
COMPLETED Phase 2

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840
COMPLETED Phase 2

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

NCT02832063
COMPLETED NA

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

NCT03268174
COMPLETED NA

Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris

NCT03243617
COMPLETED Phase 1

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

NCT02656485

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6

Therapeutic Areas

Atopic Dermatitis 2
Acne Vulgaris 1
Pruritus 1
Atopic Dermatitis Eczema 1
Migraine 1
Eczema 1

How the AOBiome early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Atopic Dermatitis (2 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

AOBiome: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

AOBiome sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share AOBiomeAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsArmata Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
AOBiome sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

AOBiome sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this AOBiome page

11 registered trials is a research-attention snapshot, not an endorsement of AOBiome or any single study.

  • None of AOBiome's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Atopic Dermatitis is the condition AOBiome studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

AOBiome pipeline card: 11 registered trials from official public datasets.Report a data error.